MedStar Authors catalog › Details for: The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. [Review]

MedStar Authors

Your cart is empty.
Normal view MARC view ISBD view

The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. [Review]

by Case, Brian C; Forrestal, Brian J; Garcia-Garcia, Hector M; Waksman, Ron; Yerasi, Charan.
Citation: Cardiovascular Revascularization Medicine. 21(4):540-548, 2020 04.; .Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: 2020; ; ; ISSN: 1878-0938.Full author list: Case BC; Forrestal BJ; Garcia-Garcia HM; Waksman R; Yerasi C.UI/PMID: 31952919.Subject(s): *Absorbable Implants | *Acute Coronary Syndrome/th [Therapy] | *Cardiovascular Agents/ad [Administration & Dosage] | *Coronary Artery Disease/th [Therapy] | *Drug-Eluting Stents | *Percutaneous Coronary Intervention/is [Instrumentation] | *Sirolimus/ad [Administration & Dosage] | Acute Coronary Syndrome/dg [Diagnostic Imaging] | Cardiovascular Agents/ae [Adverse Effects] | Coronary Artery Disease/dg [Diagnostic Imaging] | Humans | Percutaneous Coronary Intervention/ae [Adverse Effects] | Prosthesis Design | Risk Factors | Sirolimus/ae [Adverse Effects] | Time Factors | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteonActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.carrev.2019.12.039https://dx.doi.org/10.1016/j.carrev.2019.12.039 (Click here) | (Click here) Abbreviated citation: Cardiovasc Revasc Med. 21(4):540-548, 2020 04; .Local Holdings: Available in print through MWHC library: 2002 - present.Abstract: Advances in stent design and the development of bioresorbable polymers have allowed the development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus eluting stent (BP-SES). Over several noninferiority trials, the BP-SES has demonstrated itself to be a safe and effective therapy for obstructive coronary artery disease. This article reviews the current evidence of the efficacy of the BP-SES and examines its performance in high-risk populations, such as patients presenting with ST-segment myocardial infarction, chronic total occlusions, diabetes, and small vessel disease. Copyright (c) 2020 Elsevier Inc. All rights reserved.

Powered by Koha